Research

Hormonal

Semaglutide administration reduces visceral fat accumulation and improves glucose intolerance in obese mice by downregulating key lipogenic proteins (CD36, FABP5, ACSL, PLIN2) in epididymal white adipose tissue.

In this mouse study, semaglutide reduced fat mass by altering how fat cells store and process lipids, specifically by downregulating proteins like CD36 and PLIN2. This suggests that GLP-1 therapies may have direct peripheral effects on fat tissue metabolism, not just central appetite control. For humans, this supports the use of GLP-1 agonists for obesity management, though human dosing and response may vary.

ModerateSupportsMEDIUM confidence
Bioinformatics analysis showed a reduction of CD36, FABP5, ACSL, ACOX3, PLIN2, ANGPTL4, LPL, MGLL, AQP7, and PDK4 involved in the lipid metabolism in the Sema group accompanied by a decrease in visceral fat accumulation, blood lipids, and improvement in glucose intolerance.
Ruiyi Zhu et al. · Frontiers in Endocrinology · 2023

Why this rating

High-quality proteomic data (TMT/LC-MS/MS) in a controlled animal model, but results are not directly translatable to humans without clinical trials.

Source

Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice

Ruiyi Zhu et al. · Frontiers in Endocrinology · 2023

DOI 10.3389/fendo.2023.1095432

mechanism_only · n=36Cited 33×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →